

NCCN Clinical Practice Guidelines in Oncology  
(NCCN Guidelines®)

# Soft Tissue Sarcoma

Overall management of Soft Tissue Sarcoma is described in the full NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Soft Tissue Sarcoma. Visit [NCCN.org](https://www.nccn.org) to view the complete library of NCCN Guidelines®.

Reproduced with permission from the NCCN Guidelines for Soft Tissue Sarcoma V.2.2023.  
© 2023 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines and illustrations herein may not be reproduced in any form for any purpose without the express written permission of NCCN. To view the most recent and complete version of the NCCN Guidelines, go online to [NCCN.org](https://www.nccn.org). The NCCN Guidelines are a work in progress that may be refined as often as new significant data becomes available.

NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

SYSTEMIC THERAPY AGENTS AND REGIMENS WITH ACTIVITY IN SOFT TISSUE SARCOMA SUBTYPES AND AGGRESSIVE SOFT TISSUE NEOPLASMS

Inflammatory Myofibroblastic Tumor (IMT) with Anaplastic Lymphoma Kinase (ALK) Translocation	Malignant Perivascular Epithelioid Cell Tumor (PEComa) (for locally advanced unresectable or metastatic disease)	Recurrent Angiomyolipoma, Lymphangiomyomatosis
<p><b>Preferred regimens</b></p> <ul style="list-style-type: none"> <li>• Alectinib<sup>87</sup></li> <li>• Brigatinib<sup>88,89</sup></li> <li>• Ceritinib<sup>90</sup></li> <li>• Crizotinib<sup>91</sup></li> <li>• Lorlatinib<sup>92</sup></li> </ul>	<p><b>Preferred regimens</b></p> <ul style="list-style-type: none"> <li>• Albumin-bound sirolimus<sup>93,94</sup></li> </ul> <p><b>Other recommended regimens</b></p> <ul style="list-style-type: none"> <li>• Sirolimus<sup>95-98</sup></li> <li>• Everolimus<sup>99</sup></li> <li>• Temsirolimus<sup>100,101</sup></li> </ul>	<p><b>Preferred regimens</b></p> <ul style="list-style-type: none"> <li>• Sirolimus<sup>95-98</sup></li> <li>• Everolimus<sup>99</sup></li> <li>• Temsirolimus<sup>100,101</sup></li> </ul>

Footnotes and references see SARC-G, 7 of 12

Note: All recommendations are category 2A unless otherwise indicated.  
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

The National Comprehensive Cancer Network® (NCCN®) appreciates that supporting companies recognize NCCN's need for autonomy in the development of the content of NCCN resources. All NCCN Guidelines are produced completely independently. NCCN Guidelines are not intended to promote any specific therapeutic modality.

The distribution of this flashcard is supported by Aadi Bioscience.

Please see full [Prescribing Information](#) and [Important Safety Information](#).

